In a phase II trial lapatinib (1,500 mg once a day) or placebo was investigated for treatment of 60 women with HER2-positive ductal carcinoma in situ (DCIS) for three weeks before surgical resection [21]. This evidence concerns the gene ERBB2 and ductal breast carcinoma in situ.